Insider · CIK 0001991668
Scott Leftwich
Files at CLDI (Calidi Biotherapeutics, Inc.). First filing Aug 25, 2025, latest Aug 25, 2025.
In brief
Scott Leftwich files SEC Form 4 as director at CLDI (Calidi Biotherapeutics, Inc.). Since Aug 25, 2025, Scott Leftwich has reported 1 open-market buy worth $250k and 0 open-market sells worth $0, the latest filed on Aug 25, 2025.
A track record needs three past buys with six months of prices behind them; Scott Leftwich has 0, so none is measured yet.
The newest scored trade: bought $250k of CLDI on Aug 21, 2025, filed Aug 25, 2025, scored 71 (notable).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CLDI: Calidi Biotherapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 71Notable | Calidi Biotherapeutics, Inc. | $250k 125,000 shares | +2212% | 0% from low-96% from high |
Transactions
Every row this insider has filed, 10 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Non-Qualified Stock Options (right to buy)derivative | +4,000 | $0.00 | $0 | 4,000 | Aug 19, 2026 |
| Aug 21, 2025 | CLDI Calidi Biotherapeutics, Inc. | POpen-market purchase Common Stock | +125,000 | $2.00 | $250k | 130,650 | Aug 25, 2025 |
| Aug 21, 2025 | CLDI Calidi Biotherapeutics, Inc. | POpen-market purchase Warrant (right to buy)derivative | +125,000 | - | - | 125,000 | Aug 25, 2025 |
| Jul 9, 2025 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Non-Qualified Stock Options (right to buy)derivative | +137,078 | $0.00 | $0 | 137,078 | Jul 15, 2025 |
| Dec 31, 2024 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Common Stock | +11,684 | - | - | 67,774 | Jan 3, 2025 |
| Sep 20, 2024 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Non-Qualified Stock Options (right to buy)derivative | +20,217 | - | - | 20,217 | Oct 15, 2024 |
| Jun 28, 2024 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Common Stock | +67,187 | - | - | 560,873 | Jul 2, 2024 |
| Mar 29, 2024 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Common Stock | +23,783 | - | - | 493,686 | Jul 2, 2024 |
| Dec 21, 2023 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Common Stock | +8,958 | $1.80 | $16k | 469,903 | Jan 4, 2024 |
| Dec 21, 2023 | CLDI Calidi Biotherapeutics, Inc. | AGrant or award Non-Qualified Stock Options (right to buy)derivative | +70,249 | - | - | 70,249 | Jan 4, 2024 |
Questions about Scott Leftwich
Answered from the filings on this page, as of the latest one.
Is Scott Leftwich buying or selling?
Not in the last 12 months. Scott Leftwich's latest open-market trade on SEC Form 4 was bought $250k of CLDI on Aug 21, 2025.
How did Scott Leftwich's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Scott Leftwich has 0.
Where does Scott Leftwich file Form 4?
Scott Leftwich has filed Form 4 at CLDI (Calidi Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.